Sanofi has announced an evolution of its Executive Committee, bringing together a focused leadership team across its businesses, scientific organisation and key global functions as the company continues to deliver on its priorities and prepares its next strategic chapter.

Effective September 1, 2026, Sanofi's Executive Committee will comprise François Roger, Executive Vice President (EVP), Finance; Paulo Fontoura, EVP, Head of Research and Development (R&D); Manuela Buxo, EVP, Specialty Care; Thomas Triomphe, EVP, Vaccines; Thomas Grenier, EVP, General Medicines; Brendan O’Callaghan, EVP, Manufacturing and Supply; Jamie Haney, EVP, General Counsel; Véronique Jaillet, EVP, Chief People Officer, ad interim; Emmanuel Frenehard, Head of Digital and Audrey Duval, Head of Corporate Affairs and President of Sanofi France, will continue to report directly to Belén Garijo, CEO, Sanofi.

Madeleine Roach, currently Head of Business Operations, will become President and Country Lead of Sanofi Germany, Switzerland and Austria. Her current responsibilities, which focus on optimising enterprise business services, will be integrated into the finance function. Finance’s expanded remit will also include Global Partnering and Business Development, helping drive a more integrated approach across Business Development and Mergers and Acquisitions (M&As).

Thomas Triomphe will also assume responsibility for China, alongside his role as EVP, Vaccines.

Olivier Charmeil, currently EVP, General Medicines, will transition to Strategic Projects Advisor to the CEO. Throughout his career, Olivier has helped shape the company across a succession of leadership roles, with a deep and enduring commitment to its people, its business and the patients it serves. Roy Papatheodorou, currently EVP, General Counsel, has decided to leave the organisation to pursue external opportunities after over 4 years with the company, during which he has brought outstanding leadership and contributions which went beyond his role as General Counsel.

Belén Garijo, Chief Executive Officer (CEO), Sanofi, said, “This Executive Committee brings together experienced professionals who will work together to help shape our future direction, make disciplined choices, execute them with focus, and ensure we continue to deliver for our patients, our people and all our stakeholders. I would like to thank all those who have contributed to Sanofi’s success and those who will continue to shape its future. I am deeply grateful for their leadership, commitment and dedication, and I wish everyone every success for the future."